Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome

ConclusionsOverall, we noted synchronized target engagement of RBAC on resting state electrophysiology, in particular the reduction of aberrant high frequency gamma activity, across species in FXS. This finding holds promise for translational medicine approaches to drug development for FXS, synchronizing treatment study across species using well-established EEG biological markers in this field.Trial registrationThe human experiments are registered under NCT02998151.
Source: Journal of Neurodevelopmental Disorders - Category: Neurology Source Type: research